Monitor for actual execution of these sales, as the coordinated filing by a major shareholder signals potential lack of confidence. This adds to recent insider selling pressure and could weigh on the stock.
DYN drugs
DYN drug pipeline →- ▲ z-rostudirsen 8/10 Filed (BLA under FDA Priority Review); Phase 3 confirmatory trial (FORZETTO) ongoing · PDUFA date Jan 21, 2027
- ◆ z-basivarsen 7/10 Phase 3 (HARMONIA confirmatory trial, initiated March 2026); Phase 1/2 registrational cohort (ACHIEVE) fully enrolled · BLA filing Q3 2027
- ● DYNE-302 2/10
- All DYN drugs, catalysts & trials →
How the stock moved after the report
BEARISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 27 $18.04entry
- T+1 · 7mo ago +0.67%α +1.15% · $18.16
- T+5 · 7mo ago −1.83%α −2.23% · $17.71
- T+20 · 6mo ago +0.61%α −4.35% · $18.15
- T+60 · 4mo ago +28.66%α +23.88% · $23.21
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Three institutional investors affiliated with Atlas Venture, Atlas Venture Associates XI, L.P., Atlas Venture Fund XI, L.P., and Atlas Venture Opportunity Fund I, L.P., filed Form 144s to sell up to 1,050,000 shares of Dyne Therapeutics (DYN) each, totaling 3.15 million shares. This represents a coordinated insider sale by a major shareholder group.
Key Facts
- Three affiliated funds of Atlas Venture each filed to sell up to 1,050,000 shares of DYN
- Total proposed sale is 3.15 million shares
- Atlas Venture is a major institutional shareholder
- Recent insider activity shows $13.4M in sells over the past 30 days
Financial Impact
3.15 million shares, approximately $30.5 million at current $9.70 stock price
Risk Factors
- Significant insider selling could pressure the stock price
- Perception of lack of confidence from a major institutional backer
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (DYN), Batch item 1 | 0001628280-26-027252 |
| Document: 0001628280-26-027252-index.html | 0001628280-26-027253 |
| Document: 0001628280-26-027252.txt | 0001628280-26-027255 |
| 144 Filing (DYN), Batch item 4 | 0001628280-26-027253 |
| Document: 0001628280-26-027253-index.html | 0001628280-26-027252 |
| 144 Filing (DYN), Batch item 6 | 0001628280-26-027255 |
Track record
54 reports on DYN
12 of 15 bullish or bearish reports moved the stock their way by T+20. Best: +46.36% at T+60 after the May 20, 2026 report. 14 of 15 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 3/10 Entry $16.77 Now $16.70 −0.39% settles Dec 15
- Nov 13, 20263d ago 144 Neutral 2/10 Entry $17.16 Now $16.70 −2.68% settles Dec 15
- Nov 13, 20263d ago 144 Neutral 2/10 Entry $17.16 Now $16.70 −2.68% settles Dec 15
- Nov 5, 202611d ago 8-K Neutral 5/10 No price data
- Nov 5, 202611d ago Press Release Neutral 5/10 Entry $17.36 Now $16.70 −3.80% settles Dec 4
- Oct 29, 202618d ago Institutional Cluster Neutral 2/10 Entry $17.04 Now $16.70 −2.00% settles Nov 27
- Oct 22, 202625d ago Press Release Neutral 2/10 Entry $15.62 Now $16.70 +6.91% settles Nov 20
- Oct 12, 20265w ago Institutional Cluster Mixed 4/10 Entry $15.96 to $18.62 Now $16.70 +4.64% ▲ +16.67% +19.93% vs SPY
- Sep 29, 20266w ago Press Release Bullish 7/10 Entry $16.11 to $16.94 Now $16.70 +3.66% ▲ +5.15% +4.23% vs SPY
- Sep 8, 20269w ago Insider Cluster Neutral 3/10 Entry $19.19 to $15.97 Now $16.70 −12.98% ▼ −16.78% −18.72% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers